Searched for
CHINESE FOSUN PHARMA
Gland Pharma rallies 9% as Fosun mulls selling controlling stake in firmA sale would help Gland’s Chinese owner raise cash as the once-acquisitive group seeks to shore up its balance sheet. Fosun International h...
Gland Pharma slides further on weak Q2, stress at FosunThe pessimistic outlook by the rating agency triggered speculation that the Chinese firm may likely sell its stake in the Indian pharma com...
Chinese-owned Gland Pharma re-appoints Srinivas Sadu as MD & CEOGland Pharma reported revenues of Rs 3463 and a net profit of Rs 997 crore in FY21. Shares of Gland Pharma rose 1.89% to close at Rs 3360 o...
74% Chinese-owned Hyderabad pharma firm files for IPOThe fresh issue and the offer for sale together is expected to take the IPO size to around Rs 3,000 crore.
Chinese firm-backed Gland Pharma files for IPO; may raise up to Rs 6,000 croreThe company may raise up to $800 million or Rs 6,000 crore, a source with the knowledge of the matter said.
Gland Pharma seeks pitches from investment bankers to go publicGland Pharma, which is owned 74% by the Chinese major, is seeking a valuation of $3 billion, which is more than twice that of the valuation...
China’s Fosun eyes stake in Ahuja ConstructionsThe Fosun Group is amongst China’s largest privately-owned investment conglomerates with interests spanning across pharmaceuticals, real es...
Gland Pharma to leverage Fosun’s strengths for growthBiologics and biosimilar drugs are emerging hotspots, and Gland is arming itself to take a leap in this segment, which is estimated to be t...
Fosun Pharma acquires 74% stake in Gland Pharma for $1.09 billionFosun Pharma and Fosun International indirectly hold approximately 74 per cent equity interest in Gland Pharma, the joint statement added.
After Gland, Chinese pharma giant Fosun eyes API maker SymbiotecSymbiotec has been an acquisition target for other drug makers and PE players after the Indore-based company was put up for sale.
Fosun Group injects new life into Gland Pharma dealLast year, the government relaxed the foreign investment rules, allowing global companies to acquire up to 74 per cent in local drug makers...
Doklam effect? India said to block Fosun's $1.3 billion Gland purchaseThe companies haven’t been formally notified yet of the move, the people said, asking not to be identified because the information is priva...
Gland Pharma's deal with Fosun will open up new markets: Ravi Penmetsa, MD, Gland PharmaThe deal with Fosun is also an example of the excellence of India’s manufacturing capabilities. It goes with the essence of the Make in Ind...
Fosun agrees to buy KKR-backed Gland Pharma for $1.4 billion: SourceThe deal would be the first major move by the Fosun group since Guo Guangchang, founder of flagship holding firm Fosun International Ltd an...
China's Shanghai Fosun to acquire 86% stake in Gland Pharma for $1.4 billionShanghai Fosun will acquire the shares held by Gland Pharma founders Ravi Penmetsa and his family and PE giant KKR.
China's Fosun to buy KKR backed Gland Pharma for $1.4 billionFosun has agreed to acquire 96 percent stake, which includes shares held by founders of Gland Pharma Ravi Penmetsa and family and private e...
Fosun leads the race to buy Gland Pharma with $1.27 billion bidComing from behind in a closely fought race that saw US giant Baxter and private equity fund Advent make firm offers early May, Hong Kong-l...